Rocket Pharmaceuticals
RCKT
53 hedge funds and large institutions have $175M invested in Rocket Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 6 closing their positions.
1,240% more capital inflows, than outflows
Capital inflows: $112M | Capital outflows: $8.37M
567% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 6
179% more funds holding
Funds holding: 19 → 53 (+34)
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
18.93% more ownership
Funds ownership: 51.58% → 70.51% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RS Investment Management
San Francisco,
California
|
+$14.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.8M |
| 3 |
EverPoint Asset Management
Stamford,
Connecticut
|
+$9.47M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.61M |
| 5 |
BlackRock Advisors
Wilmington,
Delaware
|
+$7.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pentwater Capital Management
Naples,
Florida
|
-$3.86M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.92M |
| 3 |
TI
Telemetry Investments
New York
|
-$1.28M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$976K |
| 5 |
Polar Capital
London,
United Kingdom
|
-$231K |
RCKT Hedge Fund Activity: Q3 2015 in Review
53 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2015, worth a combined $175M — up 243% from $51M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new RCKT positions and 6 closed out — a net gain of 34 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was RS Investment Management, opening a new position worth an estimated $14.8M. The largest seller was Pentwater Capital Management, exiting entirely with an estimated $3.86M sold.
- 53 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2015, up from 19 in Q2 2015.
- Funds reported $175M of Rocket Pharmaceuticals stock for Q3 2015, up 243% quarter-over-quarter.
- 40 funds opened new Rocket Pharmaceuticals positions in Q3 2015 and 6 closed out, a net change of +34 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2015 was RS Investment Management, an estimated $14.8M added.
- The largest Rocket Pharmaceuticals seller in Q3 2015 was Pentwater Capital Management, an estimated $3.86M sold.
Based on aggregated 13F filings for Q3 2015.